VR-2076

N/A

Report date: 2026/01/23 17:55:32

Base Information

Drug NameVR-2076
Drug Alias NameICS/LABA/LAMA inhaled triple therapy (Vectura)VR2076SKP-2076
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-2 adrenergic receptor agonistsSteroid hormone receptor agonistsImmunosuppressants +[4] 
TargetsMuscarinic acetylcholine receptorBeta-2 adrenergic receptorSteroid hormone receptor
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsYes
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVectura group services LTD
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMundipharma International LtdVectura Ltd
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A